These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8641045)

  • 1. Properties of prostaglandin E1.
    Sinzinger H; Kritz H
    Circulation; 1996 Apr; 93(7):1476-7. PubMed ID: 8641045
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposome-bound prostaglandin E1 often prevents cyclic flow variations in stenosed and endothelium-injured canine coronary arteries.
    Willerson JT; Yao SK; McNatt J; Cui K; Anderson HV; Swensen C; Ostro M; Buja LM
    Circulation; 1994 Apr; 89(4):1786-91. PubMed ID: 8149544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of prostaglandin E1 on hemorheology in patients with coronary heart disease].
    Ma C
    Zhonghua Xin Xue Guan Bing Za Zhi; 1992 Apr; 20(2):107-8. PubMed ID: 1473476
    [No Abstract]   [Full Text] [Related]  

  • 4. [Coronary vasodilator agents].
    Nakamura Y
    Kokyu To Junkan; 1974 Sep; 22(9):662. PubMed ID: 4475463
    [No Abstract]   [Full Text] [Related]  

  • 5. [Study on the suppressive effect of prostaglandin E1 on endothelial hypertrophy of an autologous venous graft].
    Kunishige H
    Hokkaido Igaku Zasshi; 2005 Jan; 80(1):125-32. PubMed ID: 15796038
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prostaglandin E1: results and perspectives in clinical practice].
    Guseva NG
    Klin Med (Mosk); 2001; 79(2):4-10. PubMed ID: 11419084
    [No Abstract]   [Full Text] [Related]  

  • 7. [Coronary vasodilators: pharmacological aspect].
    Bazaugour R; Evreux JC; Evrard JP
    Lyon Med; 1972 Nov; 228(17):427-33. PubMed ID: 4658523
    [No Abstract]   [Full Text] [Related]  

  • 8. Intrapulmonary shunt fraction and prostaglandin E1.
    Heerdt PM
    Anesth Analg; 1998 Jul; 87(1):233. PubMed ID: 9661585
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T
    Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of prostaglandin E1 on the normal and ischemic heart in dogs].
    Furuya Y; Nomura Y; Nomura M; Yokoyama S; Kawamata M; Fujita M
    Masui; 1986 Jul; 35(7):1035-41. PubMed ID: 3773249
    [No Abstract]   [Full Text] [Related]  

  • 11. Pleiotropic effects of cardilopin (secondary coronary prevention).
    Kapanadze S; Dolidze N; Bakhutashvili Z; Chapidze L; Shengelia E
    Georgian Med News; 2005 Feb; (119):46-8. PubMed ID: 15834180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current problems in the conservative long-term treatment of ischemic heart disease].
    Urbaszek W; Modersohn D; Schauer J; Günther K
    Z Arztl Fortbild (Jena); 1976 Jan; 70(1):2-13. PubMed ID: 9744
    [No Abstract]   [Full Text] [Related]  

  • 13. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M; Kazama T; Ikeda T; Sato S
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of prostacyclins in acute coronary disease].
    Ogawa K; Ito T; Satake T
    Nihon Rinsho; 1983 Dec; 41(12):2795-802. PubMed ID: 6371302
    [No Abstract]   [Full Text] [Related]  

  • 15. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
    MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on pharmacokinetics, platelet function and fibrinolytic activity under various prostaglandin E1 infusion regimens.
    Simmet T; Fitscha P; Peskar BA; Sinzinger H; Rogatti W; Tilsner V
    Prog Clin Biol Res; 1987; 242():365-73. PubMed ID: 3671390
    [No Abstract]   [Full Text] [Related]  

  • 17. [Dilazep].
    Pirani R; Gruppillo P
    G Ital Cardiol; 1980; 10(10):1419-25. PubMed ID: 7016654
    [No Abstract]   [Full Text] [Related]  

  • 18. [Modification of vascular resistance and O2 utilization by prostaglandin E1].
    Stark G; Stark U; Hönigl K; Bertuch H; Pilger E; Tritthart HA
    Vasa Suppl; 1988; 26():116-9. PubMed ID: 3201357
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy and perspectives of use of vasaprostan (prostaglandin E1) in rheumatology].
    Gusev NG
    Ter Arkh; 2002; 74(5):85-8. PubMed ID: 12087918
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cormelian (Dilazep) a new coronary active substance].
    Reuter H
    Z Allgemeinmed; 1974 Oct; 50(28):1255-6. PubMed ID: 4614598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.